In breast cancer, stimulatory effects in VEGF and ANG-1 after chemoendocrine therapy, such as doxorubicin, docetaxel, tamoxifen, exemestane or letrozol, have been described with low concentrations51. Here, VEGFA is linked to breast carcinoma.